BMD-1111 is a targeted therapeutic with an Active Domain (parathyroid hormone agonist) coupled to a Binding Domain (binds type I triple-helical collagen). The Active Domain has been demonstrated to activate the PTH/PTHrP receptor, while the Binding Domain targets and localizes the treatment to bone for a localized and sustained response, with limited off-target effects including no signs of hypercalcemia even at the most efficacious doses. Preclinical efficacy has been demonstrated in multiple animal models including ovariectomized rat and provides significantly more bone repair with a single subcutaneous injection as compared to daily injection of teriparatide (a parathyroid hormone treatment).

BMD-1231 is a targeted therapeutic comprised of an Active Domain (parathyroid hormone agonist) coupled to a Binding Domain and combined with a collagen structural matrix for use as a bone graft substitute in spinal fusion procedures in lieu of autologous bone grafts. The osteogenic and bone-remodeling effects of a single dose of BMD-1231 have been demonstrated to last 4-6 months in animal models. By activating multiple components of bone formation and remodeling, BiologicsMD's approach provides a more complete repair response than other osteobiologics agents and minimizes off-target effects (e.g. hypercalcemia). The protein manufacturing process for BMD-1231 is nearing completion and the program is in pre-IDE development.

BMD-3151 and BMD-5151 are fusion of an Active Domain (parathyroid antagonist) and a Binding Domain that targets type 1 collagen and are being studied for the prevention and treatment of breast. The program is in the early preclinical development stage with animal efficacy data suggesting that the compound may prevent and treat breast cancer bone metastases. These treatments are also expected to be effective in prevention and treatment of prostate cancer bone metastases.